{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:17:03Z","timestamp":1773422223790,"version":"3.50.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Health and Medical Scientific Research Project of Shenzhen Bao\u2019an Medical Association","award":["BAYXH2024012"],"award-info":[{"award-number":["BAYXH2024012"]}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the real-world efficacy and safety of tenofovir amibufenamide (TMF) in patients with chronic hepatitis B (CHB) and to generate evidence to inform optimization of antiviral treatment selection in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study enrolled 186 patients with CHB, of whom 93 received TMF and 93 received tenofovir disoproxil fumarate (TDF) for 48\u202fweeks. The primary endpoint was the virological response rate. Secondary endpoints included the rate of serum alanine aminotransferase (ALT) normalization; changes in hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) levels; and changes in renal and bone metabolism markers, including serum creatinine, uric acid, calcium, and phosphate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 48\u202fweeks of treatment, virological response rates did not differ significantly between the TMF and TDF groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;gt;\u202f0.05). In contrast, the ALT normalization rate was significantly higher in the TMF group than in the TDF group (76.34% vs. 60.22%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). Similarly, the HBeAg seroconversion rate was markedly higher with TMF therapy (22.78% vs. 9.21%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). With respect to safety, serum creatinine levels at week 48 were significantly lower in the TMF group compared with the TDF group (77.36\u202f\u00b1\u202f16.87\u202f\u03bcmol\/L vs. 90.12\u202f\u00b1\u202f17.23\u202f\u03bcmol\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). No significant between-group differences were observed in serum uric acid, calcium, or phosphate levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In real-world clinical practice, TMF is an effective treatment for CHB. Compared with TDF, TMF is associated with superior ALT normalization and higher HBeAg seroconversion rates, along with a more favorable renal safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1774942","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T06:53:39Z","timestamp":1772088819000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of tenofovir amibufenamide in patients with chronic hepatitis B: a real-world clinical study"],"prefix":"10.3389","volume":"13","author":[{"given":"Rongshan","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Hepatology, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linling","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ai","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine","place":["Shenzhen, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL clinical practice guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3760\/cma.j.cn501113-20221204-00607","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"30","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/apt.16611","article-title":"Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B","volume":"54","author":"Liu","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s00535-022-01918-z","article-title":"Perspectives on current controversial issues in the management of chronic HBV infection","volume":"57","author":"Liaw","year":"2022","journal-title":"J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"101463","DOI":"10.1016\/j.clinre.2020.05.011","article-title":"Significant histological changes and satisfying antiviral efficacy in chronic hepatitis B virus infection patients with normal alanine aminotransferase: antiviral therapy decision in chronic HBV patients with normal ALT","volume":"45","author":"Wu","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.14218\/JCTH.2025.00162","article-title":"Interim analysis of 48-week Tenofovir Amibufenamide treatment in chronic hepatitis B patients with Normal alanine aminotransferase levels: the PROMOTE study","volume":"13","author":"Gui","year":"2025","journal-title":"J Clin Transl Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"21656","DOI":"10.1038\/s41598-024-72986-9","article-title":"Real-world study on the efficacy and safety of different treatment regimens in treatment-na\u00efve CHB patients with high viral load","volume":"14","author":"Wu","year":"2024","journal-title":"Sci Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.14218\/JCTH.2023.00417","article-title":"Five-year treatment with tenofovir alafenamide achieves high rates of viral suppression, alanine aminotransferase normalization, and favorable bone and renal safety in Chinese chronic hepatitis B patients","volume":"12","author":"Hou","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s12072-019-09943-6","article-title":"Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results","volume":"13","author":"Liang","year":"2019","journal-title":"Hepatol Int"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B: report from the 2019 EASL-AASLD HBV treatment endpoints conference","volume":"72","author":"Cornberg","year":"2020","journal-title":"J Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e14029","DOI":"10.1111\/jvh.14029","article-title":"Efficacy and safety of tenofovir amibufenamide and tenofovir alafenamide for first-time HBV-related decompensated cirrhosis","volume":"32","author":"Rong","year":"2025","journal-title":"J Viral Hepat"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/apt.16788","article-title":"Switching patients with chronic hepatitis B to tenofovir alafenamide: a review of current data","volume":"55","author":"Lim","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3760\/cma.j.cn501113-20240807-00365","article-title":"Efficacy evaluation of extending or switching to tenofovir amibufenamide in patients with chronic hepatitis B: a phase III randomized controlled study","volume":"32","author":"Liu","year":"2024","journal-title":"Zhonghua Gan Zang Bing Za Zhi"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1774942\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:33:31Z","timestamp":1773419611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1774942\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":15,"alternative-id":["10.3389\/fmed.2026.1774942"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1774942","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"article-number":"1774942"}}